CS Medica (CSMED) Q4 2024 earnings summary

Executive summary

• Q4 revenue surged to DKK 3.9m from DKK 0.073m year-over-year; full-year revenue reached DKK 8.4m, up from DKK 1.1m, driven by strong order pipeline and market expansion, though budgeted targets were missed due to production delays and a postponed deal.

• Operating loss reduced by 39% in Q4 and 30% for the year, reflecting improved cost control and operational efficiency, but liquidity constraints persist.

• Strategic partnerships, regulatory milestones, and new market entries in Germany, the US, India, and Southeast Asia underpin growth, with a focus on compliance and innovation.

• Preparations for the CANNORDIC IPO in Germany are progressing, aiming to secure capital for scaling operations and R&D.

Financial highlights

• Q4 net sales: DKK 3.9m (Q4 2022/23: DKK 0.073m); YTD: DKK 8.4m (YTD 2022/23: DKK 1.1m).

• Gross profit for Q4: DKK 1.1m (28% margin); YTD: DKK 3.2m (38% margin), slightly below target due to stock write-downs and free samples.

• Net loss for Q4: DKK -2.8m, improved from DKK -4.6m; YTD net loss: DKK -10.5m, improved from DKK -15.2m.

• Operating loss for Q4: DKK -2.8m, down from DKK -4.6m; YTD: DKK -10.5m, down from DKK -15.2m.

• Cash and equivalents at Q4 end: DKK -0.8m; equity ratio at 17% (Q4 2022/23: 40%).

Outlook and guidance

• FY 2024/25 net sales target: DKK 33.8m; gross margin target: 60%; order pipeline goal: DKK 80m.

• Strategic focus on expanding in EU, APAC, LATAM, MENA, and US, with production relocation to India to cut costs and boost profitability.

• Continued caution regarding liquidity and scalability risks, with funding stabilization a top priority.